BRCA1 degradation in response to mitochondrial damage in breast cancer cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 04 2021
Historique:
received: 17 04 2020
accepted: 22 03 2021
entrez: 23 4 2021
pubmed: 24 4 2021
medline: 9 11 2021
Statut: epublish

Résumé

BRCA1 is a well-studied tumor suppressor involved in the homologous repair of DNA damage, whereas PINK1, a mitochondrial serine/threonine kinase, is known to be involved in mitochondrial quality control. Genetic mutations of PINK1 and Parkin cause autosomal recessive early-onset Parkinson's disease. We found that in breast cancer cells, the mitochondrial targeting reagents, which all induce mitochondrial depolarization along with PINK1 upregulation, induced proteasomal BRCA1 degradation. This BRCA1 degradation was dependent on PINK1, and BRCA1 downregulation upon mitochondrial damage caused DNA double-strand breaks. BRCA1 degradation was mediated through the direct interaction with the E3 ligase Parkin. Strikingly, BRCA1 and PINK1/Parkin expression were inversely correlated in cancerous mammary glands from breast cancer patients. BRCA1 knockdown repressed cancer cell growth, and high BRCA1 expression predicted poor relapse-free survival in breast cancer patients. These observations indicate a novel mechanism by which mitochondrial damage is transmitted to the nucleus, leading to BRCA1 degradation.

Identifiants

pubmed: 33888730
doi: 10.1038/s41598-021-87698-7
pii: 10.1038/s41598-021-87698-7
pmc: PMC8062582
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
Carbonyl Cyanide m-Chlorophenyl Hydrazone 555-60-2
Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27
Protein Kinases EC 2.7.-
PTEN-induced putative kinase EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8735

Références

Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
J Cell Biol. 2014 Apr 28;205(2):143-53
pubmed: 24751536
Genes Dev. 2013 Oct 15;27(20):2274-91
pubmed: 24142877
Nature. 2014 Jun 5;510(7503):162-6
pubmed: 24784582
Oncotarget. 2015 Apr 10;6(10):7608-18
pubmed: 25797244
Oncotarget. 2015 Oct 14;8(49):86799-86815
pubmed: 29156836
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7363-7370
pubmed: 30918126
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Hum Pathol. 2011 Jan;42(1):75-87
pubmed: 20971498
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Sci Rep. 2012;2:1002
pubmed: 23256036
FEBS Lett. 2010 Sep 10;584(17):3717-24
pubmed: 20493860
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Nat Commun. 2017 Nov 28;8(1):1823
pubmed: 29180628
J Virol. 2012 Jul;86(14):7466-72
pubmed: 22553330
Neuron. 2014 Jul 16;83(2):266-282
pubmed: 25033177
J Cell Biol. 2010 Apr 19;189(2):211-21
pubmed: 20404107
Biochem Biophys Res Commun. 2014 Feb 21;444(4):549-54
pubmed: 24472556
Nat Rev Mol Cell Biol. 2011 Jan;12(1):9-14
pubmed: 21179058
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
J Biol Chem. 2004 Aug 6;279(32):33909-18
pubmed: 15166217
J Biol Chem. 2012 Nov 30;287(49):41014-22
pubmed: 23086937
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9645-E9654
pubmed: 29042514
Nat Commun. 2016 Nov 15;7:13398
pubmed: 27845331
Neuron. 2015 Jan 21;85(2):257-73
pubmed: 25611507
BMC Cancer. 2011 Jun 13;11:246
pubmed: 21668996
Mol Endocrinol. 2007 Mar;21(3):651-63
pubmed: 17185394
Mol Neurobiol. 2018 Aug;55(8):6788-6800
pubmed: 29349575
Cancer Res. 2016 Aug 15;76(16):4708-19
pubmed: 27325644
Physiol Genomics. 2003 Dec 16;16(1):29-37
pubmed: 14679299
PLoS Biol. 2010 Jan 26;8(1):e1000298
pubmed: 20126261
Nature. 2013 Apr 18;496(7445):372-6
pubmed: 23503661
Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):633-640
pubmed: 28017650
Scientifica (Cairo). 2012;2012:796808
pubmed: 24278741
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7697-E7706
pubmed: 28847964
Cell Cycle. 2009 Feb 1;8(3):498-504
pubmed: 19177017
Biochem J. 2014 May 15;460(1):127-39
pubmed: 24660806
Nat Commun. 2015 Nov 30;6:8897
pubmed: 26615780
Biology (Basel). 2013 Jan 02;2(1):40-63
pubmed: 24832651
Oncogene. 2002 Sep 9;21(40):6222-7
pubmed: 12214252
Oncogene. 2006 Sep 25;25(43):5854-63
pubmed: 16998500
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12075-80
pubmed: 9342365
Nature. 2018 Jul;559(7714):410-414
pubmed: 29995846
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Biol Chem. 2001 May 4;276(18):14537-40
pubmed: 11278247
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Sci Rep. 2017 May 18;7(1):2093
pubmed: 28522833
Cancer Res. 2010 Aug 1;70(15):6384-92
pubmed: 20631078
Oncogene. 2015 Mar 12;34(11):1363-74
pubmed: 24681957

Auteurs

Kana Miyahara (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Naoharu Takano (N)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan. ntakano@tokyo-med.ac.jp.

Yumiko Yamada (Y)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Hiromi Kazama (H)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Mayumi Tokuhisa (M)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Hirotsugu Hino (H)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Koji Fujita (K)

Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Edward Barroga (E)

St. Luke's International University, Tokyo, 104-0044, Japan.

Masaki Hiramoto (M)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Hiroshi Handa (H)

Department of Nanoparticle Translational Research, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Masahiko Kuroda (M)

Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Takashi Ishikawa (T)

Department of Breast Oncology and Surgery, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan.

Keisuke Miyazawa (K)

Department of Biochemistry, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan. miyazawa@tokyo-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH